Literature DB >> 10347251

Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs.

M Quack1, C Carlberg.   

Abstract

The transcription factor VDR is the nuclear receptor for 1alpha, 25-dihydroxyvitamin D3 (VD) and the mediator of all genomic actions of the nuclear hormone and its synthetic analogs. The sharp biological profile of the model VD analog 1(S), 3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E), 3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene (EB1089) (i.e., its high antiproliferative effect combined with low calcemic actions) has been correlated with the selectivity of EB1089 to activate heterodimeric complexes of VDR with its partner retinoid X receptor (RXR) on VD response elements (VDREs). These VDREs are formed by an inverted palindromic arrangement of two hexameric core binding motifs spaced by nine nucleotides (IP9) rather than VDREs that are formed by direct repeats with three intervening nucleotides (DR3). In this report, ligand-dependent gel-shift assays were used for a comparison of the ability of VD and EB1089 to stabilize VDR-RXR heterodimers on these two VDRE types. The gel-shift assays revealed EB1089 to be more sensitive for complexes on IP9-type VDREs than on DR3-type VDREs. In addition, a gel-shift clipping method was established to identify and compare complexes of ligand-stabilized VDR-RXR heterodimers on different VDREs. On each VDRE, two complexes could be discriminated that seemed to contain different functional conformations of the VDR and allowed a more differential view on DNA-complexed VDR-RXR heterodimers. The VDR-RXR conformation (which was more ligand-sensitive) gained through EB1089 a higher affinity (7-fold) for DNA binding and a more sensitive (9-fold) activation of an IP9-type VDRE than of a DR3-type VDRE, whereas with the natural hormone VD, no VDRE-type preference could be observed. This indicates that promoter selectivity of VDR ligands is based on their property to selectively increase affinity for VDREs and very sensitively stabilize VDR conformations in VDR-RXR-VDRE complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347251     DOI: 10.1124/mol.55.6.1077

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

2.  An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling.

Authors:  S Kronenberg; C Esser; C Carlberg
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

3.  All natural DR3-type vitamin D response elements show a similar functionality in vitro.

Authors:  A Toell; P Polly; C Carlberg
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

Review 4.  Role of Neural Stem Cells and Vitamin D Receptor (VDR)-Mediated Cellular Signaling in the Mitigation of Neurological Diseases.

Authors:  Chinnappa A Uthaiah; Narasimha M Beeraka; R Rajalakshmi; C M Ramya; SubbaRao V Madhunapantula
Journal:  Mol Neurobiol       Date:  2022-04-27       Impact factor: 5.590

Review 5.  Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Authors:  Diego Brancaccio; Jürgen Bommer; Daniel Coyne
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung.

Authors:  Angela K Ormerod; Zhenlan Xing; Nancy G Pedigo; Anjali Mishra; David M Kaetzel
Journal:  Exp Lung Res       Date:  2008-05       Impact factor: 2.459

Review 7.  New Roles for Vitamin D Superagonists: From COVID to Cancer.

Authors:  David J Easty; Christine J Farr; Bryan T Hennessy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

Review 8.  The future of vitamin D analogs.

Authors:  Carlien Leyssens; Lieve Verlinden; Annemieke Verstuyf
Journal:  Front Physiol       Date:  2014-04-03       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.